Type 2 diabetes hides two separate decisions under one disease name, and the evidence answers them differently. Read them apart.
Prevention. A person with prediabetes who joins an intensive lifestyle programme lowers their chance of developing diabetes by more than the standard first-line drug, metformin, does. The programme works across nearly every kind of person; the drug pays off mainly in the younger, heavier, more hyperglycaemic. What lifestyle buys is a delayed diagnosis. Whether it also prevents heart attacks or extends life, in a person who is otherwise low-risk, is not shown.
Remission. A person diagnosed within the last few years can push diabetes into remission — normal blood sugar with no glucose-lowering drugs — by losing a large amount of weight and keeping it off. Remission climbs steeply with the kilograms lost, and the strongest evidence rides a low-calorie formula-diet programme. The operative lever is the weight loss, not the diet’s macronutrient label: cutting carbohydrate is one workable route to the deficit, not a separate cure. The unsettled question is how long remission lasts: the randomised evidence runs only a year or two — the one five-year signal is observational — and remission relapses if the weight comes back.
One thread runs through both decisions: what you choose has to be something you keep doing. A programme that is abandoned reverts, whether it is a prevention curriculum, a formula diet, or a drug.
For prediabetes, changing how you live out-prevents the drug
The Diabetes Prevention Program (DPP) is the head-to-head. It randomised 3,234 adults with prediabetes (mean BMI 34, age 51) to an intensive lifestyle programme — a goal of at least 7% weight loss and 150 minutes of activity a week, with a 16-lesson curriculum and case managers — to metformin 850 mg twice daily, or to placebo, and followed incident diabetes over a mean 2.8 years (Knowler, 2002). Both active arms worked; the behaviour change worked better: «The lifestyle intervention reduced the incidence by 58 percent (95 percent confidence interval, 48 to 66 percent) and metformin by 31 percent (95 percent confidence interval, 17 to 43 percent), as compared with placebo; the lifestyle intervention was significantly more effective than metformin.» (Knowler, 2002)
On the frame that carries the decision — absolute yield — the gap is roughly two to one -> Baseline Risk and the Relative-Absolute Split.
| Placebo | Metformin | Lifestyle | |
|---|---|---|---|
| Incidence (cases/100 person-yr) | 11.0 | 7.8 | 4.8 |
| Relative reduction vs placebo | — | 31% (17-43) | 58% (48-66) |
| Cumulative incidence at 3 yr | 28.9% | 21.7% | 14.4% |
| NNT (3 yr, to prevent one case) | — | 13.9 | 6.9 |
To prevent one case of diabetes over three years, about 7 people need the lifestyle programme versus about 14 for metformin (Knowler, 2002).
The lifestyle win is replicated; the head-to-head against the drug is not. Two other randomised trials, on two other continents, found the same lifestyle effect. The Finnish DPS (522 adults with impaired glucose tolerance) cut incidence 58% (HR 0.4, 95% CI 0.3-0.7), an NNT of 5 over five years (Tuomilehto et al., 2001). Da Qing (577 Chinese adults) cut it 31% by diet, 46% by exercise, and 42% by both over six years (Pan et al., 1997). The defensible claim is three independent trials, concordant direction, relative reductions of 31-58% — read against each trial’s own follow-up, not pooled into one number. Neither Finnish nor Da Qing carried a metformin arm, so the claim that lifestyle beats the drug still rests on DPP alone.
Da Qing adds one practical refinement: combining diet and structured exercise was not additive — the combined arm (42%) did not beat exercise alone (46%) — so a single well-adhered component captures most of the available prevention (Pan et al., 1997).
The two active arms behave differently by stratum, and that decides who each is for. Lifestyle was effective across essentially every subgroup — sex, ethnicity, and age (numerically largest in the oldest). Metformin’s effect was concentrated in the more obese and more hyperglycaemic and ran near-null at the lean, near-normal-fasting end: a 3% (non-significant) reduction at BMI 22 to <30, and 15% (non-significant) at fasting glucose 95-109 mg/dl, against 53% at BMI ≥35 (Knowler, 2002). So lifestyle is a broad-spectrum lever and metformin is a stratum-specific one.
Weight loss carried most of the lifestyle effect, but activity has its own channel. A DPP mediation analysis found each kilogram lost cut diabetes risk about 16%, and weight change dominated the model (Hamman et al., 2006). Yet among participants who missed the weight-loss goal, those who hit the activity goal still had 44% lower incidence — and the Finnish trial found the same pattern in a different cohort (Hamman et al., 2006)(Tuomilehto et al., 2001). The read: steer toward sustained weight loss, but activity is a partly independent second lever, valuable for the person who cannot reach the weight target.
These numbers are the effect of a programme as actually adhered to: DPP’s lifestyle arm delivered its 58% even though only 38% still held a 7% loss at the final visit (Knowler, 2002).
Metformin’s ceiling, and why the prevention win is a diagnosis rather than a heart attack
Metformin is the default first-line drug for this stratum, so the lifestyle lever has to be sized at the margin, net of what the drug already delivers. Metformin is real (31% relative reduction, NNT 14), cheap, and long-established — but three limits bound it. It is stratum-selective, buying little in the lean and near-normal-fasting person above. Its main tax is gastrointestinal (77.8 adverse GI events per 100 person-years versus 12.9 on lifestyle in DPP). And adherence decays: in long-term follow-up, study-metformin use fell from 77% to 41% (Knowler, 2002)(Goldberg et al., 2022).
Lifestyle roughly doubles the absolute prevention and acts on a broader defect — the insulin resistance and post-load glucose that the drug leaves largely untouched. So the drug cannot substitute for it; metformin is the realistic alternative only where the programme is not delivered, or not enough. Which agent, and any dosing, is a prescriber’s call and outside this appraisal. (inferred from Knowler, 2002)
What prevention demonstrably buys is a delayed diagnosis, not a prevented heart attack. DPP’s endpoint is diabetes incidence — a disease onset, one rung above a pure lab surrogate, but not a hard cardiovascular or mortality outcome -> Surrogate Outcomes. Followed a median 21 years, the same three arms were null on cardiovascular events: metformin MACE HR 1.03 (95% CI 0.78-1.37) and lifestyle HR 1.14 (0.87-1.50) versus placebo — point estimates trending the wrong way for lifestyle (Goldberg et al., 2022). This is a bounded null, not a demonstration of no effect: the cohort was low-risk and heavily treated by then (statins 56-62%, antihypertensives 68-74%), leaving little absolute risk to remove.
The same prevention question, asked in a higher-risk cohort over 30 years (Da Qing), did show a cardiovascular benefit, MACE HR 0.74 (0.59-0.92) (Goldberg et al., 2022). Absolute benefit scales with baseline risk. So the honest statement to a low-risk prediabetic person is that lifestyle prevents the diagnosis; the hard-outcome payoff, if any, needs higher risk or a longer horizon than the evidence has yet followed -> Baseline Risk and the Relative-Absolute Split.
For recently diagnosed diabetes, sustained weight loss can drive it into remission
Remission is a defined endpoint, not a loose “reversal”. DiRECT set it as the primary outcome and specified it precisely: «Co-primary outcomes were weight loss of 15 kg or more, and remission of diabetes, defined as glycated haemoglobin (HbA1c) of less than 6·5% (<48 mmol/mol) after at least 2 months off all antidiabetic medications, from baseline to 12 months.» (Lean et al., 2018) The programme it tested — Counterweight-Plus — runs an 825-853 kcal/day formula diet for three months, a stepped food reintroduction, then structured maintenance, and «All oral antidiabetic and antihypertensive drugs were discontinued on day 1» (Lean et al., 2018). It enrolled adults with T2D diagnosed within six years, BMI 27-45, not on insulin, in routine primary care.
The result was large. Remission reached 46% (68 of 149) versus 4% in usual care (OR 19.7, 95% CI 7.8-49.8); mean weight fell 10.0 kg versus 1.0; and 73.6% of the programme group were on zero oral antidiabetic drugs at 12 months versus 18.2% (Lean et al., 2018). Remission scales with the weight lost, in a clean monotone gradient with no plateau below 15 kg:
| Weight change at 12 months | Remission rate |
|---|---|
| Weight gained | 0% (0 of 76) |
| 0-5 kg loss | 7% |
| 5-10 kg loss | 34% |
| 10-15 kg loss | 57% |
| ≥15 kg loss | 86% (31 of 36) |
The gradient is direct evidence that the amount of weight lost, not the diet’s composition, is the operative variable — it holds across the whole population regardless of how the loss was achieved. The gold-tier umbrella review of T2D diets places total diet replacement (DiRECT plus one sister trial) at the single GRADE-high cell of the whole remission map: median 54% remission (range 46-61) versus 4-12% for usual care. That sits above formula meal replacement (11%, moderate), Mediterranean (15%, low), and ketogenic (20%, very low) (Churuangsuk et al., 2021) -> Total Diet Replacement and Type 2 Diabetes Remission.
The lever reaches below the trial’s BMI floor. DiRECT required BMI ≥27, so it is silent on the roughly one-third of people who develop T2D at normal weight — a group routinely not offered weight loss at all. Taylor’s work extends the lever there: 36% of newly-diagnosed cases occurred at BMI <25, and a normal-weight person reaches normoglycaemia at a smaller required loss (about 13% of body weight versus 21% for the whole cohort) (Taylor & Holman, 2014). A normal-weight person with short-duration diabetes is a candidate for the same energy-deficit lever -> Body Fat.
Durability is the open edge, and adherence is part of the effect. DiRECT’s result is at 12 months; it was designed for maintenance, but even so weight regained partly after the formula phase (down 14.5 kg during total diet replacement, then up ~2.9 kg through reintroduction and maintenance), and about a quarter of participants dropped out — the programme’s real-world acceptability ceiling (Lean et al., 2018). A separate five-year UK cohort corroborates the direction: every 1 kg lost was linked to a 7% higher chance of remission at five years, and a >10% first-year loss to a 70% higher chance (Churuangsuk et al., 2021). Remission also becomes less likely the longer the disease has been present, which is why acting early matters — «remission should be attempted as early as possible from diabetes diagnosis», with the highest rates in newly-diagnosed or under-two-year disease (Churuangsuk et al., 2021). A remission that relapses when weight returns is a smaller benefit than one that holds, and no held randomised trial follows remission past about two years — the one five-year signal is observational.
Carbohydrate restriction is one route to the weight loss, not a separate cure
The popular claim is that cutting carbohydrate specifically reverses diabetes. The evidence says the answer depends entirely on how remission is defined — and points back to weight. A meta-analysis of 23 low-carbohydrate trials (defined as <26% of energy or <130 g/day) found that with medication allowed to continue, remission by HbA1c climbed sharply at six months (risk difference 0.32, an NNT of about 3). But under the definition that also requires coming off medication — the endpoint that matters — the pooled effect was never statistically significant at any timepoint, and the 12-month estimate was negative (Goldenberg et al., 2021).
In the narrower stratum where a low-carb diet would most plausibly be offered — people not on insulin — medication-free remission is significant at six months (RD 0.20, NNT 5). But that rescue carries no durability estimate, and the low-carb weight advantage itself decays from −3.46 kg at six months to +0.29 kg by twelve as the weight is regained (Goldenberg et al., 2021).
A remission effect that fades in step with its weight advantage is consistent with a weight-loss effect delivered by a low-carb route, not a carbohydrate effect independent of weight. DiRECT closes the argument: it reaches 46% remission on a formula diet that is 59% carbohydrate — the opposite of low-carb — so carbohydrate restriction is not necessary for remission (Lean et al., 2018).
No randomised trial has tested the low-carb remission claim on its own terms: «No RCT has evaluated LCDs/ketogenic diets for type 2 diabetes remission.» (Churuangsuk et al., 2021) The much-cited keto figure is a single non-randomised study at the bottom GRADE tier. (Goldenberg et al., 2021; inferred from Lean et al., 2018)
What carbohydrate restriction does carry firmly is a glycaemic and deprescribing signal, not a remission one. A second gold umbrella review found low-carb (<26% energy) cut HbA1c by 0.47% (high certainty) and «reduced the use of drug treatments by an additional 24 per 100 individuals» (risk difference 0.24, moderate certainty) — the firmest clinical outcome in either umbrella (Szczerba et al., 2023). So a person who adheres to a low-carb diet can reasonably expect better glycaemia and fewer drugs; a durable, medication-free remission attributable to the carbohydrate cut, beyond the weight it produces, is not shown -> Carbohydrate Restriction and Type 2 Diabetes Remission.
For glycaemic control, no macronutrient pattern beats energy balance — with two caveats
Across the whole T2D-diet literature, the same verdict recurs: no macronutrient profile wins. The gold-tier umbrella review of 19 meta-analyses concluded they «do not support any particular macronutrient profile or style over others», and that «Very low energy diets and formula meal replacement appear the most effective approaches, generally providing less energy than self-administered food-based diets» (Churuangsuk et al., 2021). Low-carbohydrate versus higher-carbohydrate for weight is the single highest-certainty cell in the map — a GRADE-high finding of no meaningful difference, not a gap in the evidence (Churuangsuk et al., 2021). HbA1c broadly followed weight loss, and a composition-specific, weight-independent glycaemic edge could not be separated out. The review’s own summary: «The main contributor to HbA1c reduction and remission appears to be weight loss, irrespective of diet type.» (Churuangsuk et al., 2021)
Caveat one: composition begins to separate on the markers, not on weight. On weight and waist, composition is null; but on glycaemia and lipids the choice of diet moves a different outcome — the low-carb HbA1c and triglyceride effects above are real (Szczerba et al., 2023). Once the energy and weight lever is set, pick the pattern by which marker you most want to move, and by what you will adhere to.
Caveat two: glycaemic index is a proxy, not a separate lever. High-GI diets track higher risk of T2D (RR 1.27, 95% CI 1.21-1.34) and cardiovascular disease (1.15), but at GRADE-low certainty, and GI rides together with fibre and whole-grain content in whole-food diets with almost no study separating them (Jenkins et al., 2024). Steering by fibre and whole-grain content — more legumes, intact and minimally-refined carbohydrate, fewer refined and sugary ones — captures most of what steering by GI would, and is the same advice -> Glycaemic Index and Glycaemic Load and Chronic Disease.
A related point on measurement: insulin resistance sits upstream of both prevention and remission, and a cheap fasting readout, the triglyceride-glucose (TyG) index, flags the insulin-resistant person from two routine labs. It predicts cardiovascular incidence (CAD HR 2.01) but is null on mortality (CV mortality 1.10, all-cause 1.08, both confidence intervals crossing 1) and adds nothing over an existing risk score (Liu et al., 2022). Use it to place someone in the insulin-resistant stratum, not as a target to steer down -> Insulin Resistance Surrogates and Cardiovascular Risk.
What to do, by where you stand
If you have prediabetes. An intensive lifestyle programme is first-line: a ~7% weight-loss goal and ~150 minutes of activity a week, delivered with structure and follow-up. It roughly doubles the absolute prevention of metformin and works across strata. Metformin is the realistic fallback where the programme is not available or not enough, and it earns its place most in the younger, more obese, more hyperglycaemic person; it buys little in the lean with near-normal fasting glucose. Understand what you are buying: a delayed diagnosis, with a hard-outcome (heart-attack, mortality) payoff that is proven only where baseline risk is high. A GLP-1 drug is a further comparator lever, appraised separately -> GLP-1 Drugs.
If you were recently diagnosed (within a few years, not on insulin). Remission is on the table, and the target is the largest sustained weight loss you can hold — acted on early, because the window narrows with disease duration. A structured total-diet-replacement programme has the strongest evidence, but the format matters less than the deficit and the adherence: any energy-controlling approach you will stick to is defensible, carbohydrate restriction included. Manage medication withdrawal with a clinician — the endpoint is normal HbA1c off drugs — and expect that the loss must be maintained, because remission relapses if the weight returns. This lever also applies below BMI 27, where trials routinely exclude people but the mechanism does not.
What the evidence still cannot see
- The GLP-1 leg on T2D outcomes is thin here. These drugs reverse prediabetes to normoglycaemia and sharply cut progression to diabetes, and they are the strongest weight lever -> GLP-1 Drugs. But a dedicated head-to-head of a GLP-1 drug versus lifestyle for T2D remission, and its durability, is not held in this cut, and the strongest-weight-loss agent (tirzepatide) has no hard-outcome trial at all. Named gap.
- Bariatric surgery as a remission comparator is not held. DiRECT argues surgery works through weight loss rather than any surgical effect, and surgery anchors a durable mortality benefit elsewhere in the fabric -> Body Fat — but no dedicated source on surgical remission rates and durability is held here. Named gap.
- Long-term (5-10 year) remission durability is unmeasured. The randomised evidence runs to about one to two years; the one five-year signal is observational. Whether remission achieved by any lifestyle route holds over a decade is genuinely unknown — insufficient evidence, not a null.
The loop is open. Everything above grades the coherence and source-fidelity of the evidence, not its correspondence to your realised outcome. No operation here has tested these recommendations against what actually happened to people who followed them.
Evidence box
Question ’For an adult at risk of, or living with early, type 2 diabetes, what does the evidence show about the modifiable lifestyle levers on incidence and on remission — direction, magnitude, durability, for whom — how do weight loss, diet composition, total diet replacement, and physical activity compare, and where does lifestyle sit against the standard first-line drug?‘ Evidence included 12 sources — 4 gold, 7 high, 1 moderate Overall certainty Medium (see Rating Certainty of Evidence) Source-selection note 1 source(s) below the gold evidence bar feed this page: Taylor (mechanism, moderate). Each labelled by tier; none load-bearing for the core claims. Last updated 2026-09-09 · Independently reviewed: No · Full edit history